Skip to main content

Advertisement

SpringerLink
Log in

Psychopharmacology in Psycho-oncology

  • Complex Medical-Psychiatric Issues (MB Riba, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Psychopharmacological intervention is a major clinical and research area in oncology and palliative care. Over the last 35 years, psychotropic drugs have been shown to have a number of important indications for the treatment of the most common psychiatric disorders, such as depression, anxiety, stress-related syndromes, severe adjustment disorders, sleep disorders and delirium, which combined affect at least 30-40% of patients with cancer and even a higher percentage of patients in an advanced phase of illness. The availability of new drugs, with less side-effects and safer pharmacological profiles, has been a major advance in clinical psycho-oncology. Interestingly, several drugs have also been found to be helpful for the adjuvant treatment of cancer-related symptoms, such as pain, hot flashes, pruritus, nausea and vomiting, fatigue, and cognitive impairment, making psychopharmacology an important tool for the improvement of cancer patients’ quality of life. The aim of this paper is to summarize recent relevant data concerning the use of psychotropic drugs, namely antidepressants, anxiolytics, antipsychotics, anticonvulsants and psychostimulants in patients with cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Grassi L, Watson M, on behalf of the IPOS Federation of Psycho-Oncology Societies’ co-authors. Psychosocial care in cancer: an overview of psychosocial programmes and national cancer plans of countries within the International Federation of Psycho-Oncology Societies. Psychooncology. 2012;21:1027–33.

    Article  PubMed  Google Scholar 

  2. Holland J, Watson M, Dunn J. The IPOS New International Standard of Quality Cancer Care: integrating the psychosocial domain into routine care. Psychooncology. 2011;20:677–80.

    Article  PubMed  Google Scholar 

  3. Thekdi SM, Irarrazaval ME, Dunn L. Psychopharmacological interventions. In: Grassi L, Riba M, editors. Clinical Psycho-Oncology: an international perspective. Wiley: Chichester; 2012. p. 109–26.

    Chapter  Google Scholar 

  4. •• Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160–74. This is a meta-analysis of the most significant studies in the field of oncology, hematology, and palliative care regarding the prevalence of psychiatric disorders among cancer patients.

    Article  PubMed  Google Scholar 

  5. • Singer S, Das-Munshi J, Brähler E. Prevalence of mental health conditions in cancer patients in acute care–a meta-analysis. Ann Oncol. 2010;21:925–30. This is a study evaluating the prevalence of psychiatric disorders in cancer inpatients in acute care.

    Article  PubMed  CAS  Google Scholar 

  6. Brocken P, Prins JB, Dekhuijzen PN, van der Heijden HF. The faster the better?—A systematic review on distress in the diagnostic phase of suspected cancer, and the influence of rapid diagnostic pathways. Psychooncology. 2012;21:1–10.

    PubMed  Google Scholar 

  7. Caraceni A, Grassi L. Delirium: acute confusional states in palliative medicine. 2nd ed. Oxford: Oxford University Press; 2011.

    Google Scholar 

  8. Derogatis LR, Feldstein M, Morrow G, et al. A survey of psychotropic drug prescriptions in an oncology population. Cancer. 1979;44:1919–29.

    Article  PubMed  CAS  Google Scholar 

  9. Stiefel FC, Kornblith AB, Holland JC. Changes in prescription patterns of psychotropic drugs for cancer patients during a 10-year period. Cancer. 1990;65:1048–53.

    Article  PubMed  CAS  Google Scholar 

  10. • Desplenter F, Bond C, Watson M, Burton C, Murchie P, Lee AJ, et al. Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case–control study. Br J Cancer. 2012;107:1644–51. The study quantified the higher incidence of new emotional distress in cancer patients in the first year post diagnosis and the use of psychotropic drugs.

    Article  PubMed  CAS  Google Scholar 

  11. De Bock GH, Musters RF, Bos HJ, Schröder CP, Mourits MJ, de Jong-van den Berg LT. Psychotropic medication during endocrine treatment for breast cancer. Support Care Cancer. 2012;20:1533–40.

    Article  PubMed  Google Scholar 

  12. Ng CG, Boks MP, Smeets HM, Zainal NZ, de Wit NJ. Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands. Psychooncology. 2013;22:762–7.

    Article  PubMed  Google Scholar 

  13. Farriols C, Ferrández O, Planas J, et al. Changes in the prescription of psychotropic drugs in the palliative care of advanced cancer patients over a seven-year period. J Pain Symptom Manage. 2012;43:945–52.

    Article  PubMed  Google Scholar 

  14. Ng CG, Boks MP, Zainal NZ, de Wit NJ. The prevalence and pharmacotherapy of depression in cancer patients. J Affect Disord. 2011;131:1–7.

    Article  PubMed  CAS  Google Scholar 

  15. Grassi L, Nanni MG, Uchitomi Y, Riba M. Pharmacotherapy of depression in people with cancer. In: Kissane DW, Maj M, Sartorius N, editors. Depression and cancer. Chichester: Wiley; 2011. p. 151–76.

    Google Scholar 

  16. • Hart SL, Hoyt MA, Diefenbach M, et al. Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. J Natl Cancer Inst. 2012;104:990–1004. This study suggests that psychological and pharmacologic approaches can be targeted productively toward cancer patients with elevated depressive symptoms.

    Article  PubMed  Google Scholar 

  17. • Laoutidis ZG. Mathiak K- Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry. 2013;13:140. doi:10.1186/1471-244X-13-140. This meta-analysis suggests that antidepressants can be effective in treating depressive symptoms besides clinical depression.

  18. Rayner L, Price A, Hotopf M, Higginson IJ. The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur J Cancer. 2011;47:702–12.

    Article  PubMed  Google Scholar 

  19. Jongen JL, Huijsman ML, Jessurun J, et al. The evidence for pharmacologic treatment of neuropathic cancer pain: beneficial and adverse effects. J Pain Symptom Manage. 2013. doi:10.1016/j.jpainsymman.2012.10.230 [Epub ahead of print].

    PubMed  Google Scholar 

  20. Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. Drugs. 2008;68:2611–32.

    Article  PubMed  CAS  Google Scholar 

  21. Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med. 2011;25:553–39.

    Article  PubMed  Google Scholar 

  22. Ripamonti C, Santini D, Maranzano E, Berti M, Roila F, on behalf of the ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncology. 2012;23(Supplement 7):139–54.

    Google Scholar 

  23. Smith EM, Pang H, Cirrincione C, et al. Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–67.

    Article  PubMed  CAS  Google Scholar 

  24. Matsuoka H, Makimura C, Koyama A, Otsuka M, Okamoto W, et al. Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. Anticancer Res. 2012;32:1805–9.

    PubMed  CAS  Google Scholar 

  25. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012.

  26. Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl). 2007;16:351–4.

    Article  CAS  Google Scholar 

  27. Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care. 2010;27:106–10.

    Article  PubMed  Google Scholar 

  28. Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol. 2001;19:895–908.

    PubMed  CAS  Google Scholar 

  29. Palesh OG, Mustian KM, Peppone LJ, Janelsins M, et al. Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: a trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Sleep Med. 2012;13:1184–90.

    Article  PubMed  Google Scholar 

  30. Tanimukai H, Murai T, Okazaki N, Matsuda Y, et al. An observational study of insomnia and nightmare treated with trazodone in patients with advanced cancer. Am J Hosp Palliat Care. 2013;30:359–62.

    Article  PubMed  Google Scholar 

  31. Morrow PK, Mattair DN, Hortobagyi GN. Hot flashes: a review of pathophysiology and treatment modalities. Oncologist. 2011;16:1658–64.

    Article  PubMed  CAS  Google Scholar 

  32. Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry. 2008;165:1251–5.

    Article  PubMed  Google Scholar 

  33. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009;70:1688–97.

    Article  PubMed  CAS  Google Scholar 

  34. • Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab. 2011;12:570–7. The article provides an updated review of clinically relevant metabolic drug interactions between selected anticancer drugs, SSRIs, and Hypericum extract, showing the inhibiting effect on one or more cytochrome P450 isoenzymes (CYPs), inducing effect on CYP3A4 and P-glycoprotein (P-gp), with reduction of plasma concentrations of anticancer durgs (e.g., imatinib, irinotecan and docetaxel).

    PubMed  CAS  Google Scholar 

  35. L’Espérance S, Frenette S, Dionne A, Dionne JY. Comité de l’évolution des pratiques en oncologie (CEPO) Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer. 2013;21:1461–74.

    Article  PubMed  Google Scholar 

  36. Binkhorst L, Mathijssen RH, van Herk-Sukel MP et al. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat. 2013.

  37. •• Breitbart W, Alici-Evcimen Y. Update on psychotropic medications for cancer-related fatigue. J Natl Compr Canc Netw. 2007;5:1081–91. The paper reviews the most important psychotropic drugs that have been studied for cancer-related fatigue, such as psychostimulants, wakefulness-promoting agents, and antidepressants. It also indicates that, studies are currently limited and that randomized, placebo-controlled trials with specific agents are needed.

    PubMed  Google Scholar 

  38. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst. 2008;100:1155–66.

    Article  PubMed  CAS  Google Scholar 

  39. Dodd S, Malhi GS, Tiller J, et al. A consensus statement for safety monitoring guidelines of treatments for major depressive disorder. Austr New Zeal J Psychiatry. 2011;45:712–25.

    Article  Google Scholar 

  40. Mazzocato C, Stiefel F, Buclin T, Berney A. Psychopharmacology in supportive care of cancer: a review for the clinician: II. Neuroleptics. Support Care Cancer. 2000;8:89–97.

    Article  PubMed  CAS  Google Scholar 

  41. Candy B, Jackson KC, Jones L, Leurent B, Tookman A, King M. Drug therapy for delirium in terminally ill adult patients. Cochrane Database Syst Rev. 2012;11, CD004770.

    PubMed  Google Scholar 

  42. •• Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol. 2012;30:1206–14. This article presents evidence-based recommendations based on the results of pharmacologic and nonpharmacologic studies of the treatment and prevention of delirium.

    Article  PubMed  CAS  Google Scholar 

  43. Kishi Y, Kato M, Okuyama T, Thurber S. Treatment of delirium with risperidone in cancer patients. Psychiatry Clin Neurosci. 2012;66:411–7.

    Article  PubMed  CAS  Google Scholar 

  44. Elsayem A, Bush SH, Munsell MF, Curry 3rd E, Calderon BB, Paraskevopoulos T, et al. Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study. J Pain Symptom Manage. 2010;40:774–82.

    Article  PubMed  CAS  Google Scholar 

  45. Hui D, Reddy A, Palla S, Bruera E. Neuroleptic prescription pattern for delirium in patients with advanced cancer. J Palliat Care. 2011;27:141–7.

    PubMed  Google Scholar 

  46. Hui D, Bush SH, Gallo LE, Palmer JL, Yennurajalingam S, Bruera E. Neuroleptic dose in the management of delirium in patients with advanced cancer. J Pain Symptom Manage. 2010;39:186–96.

    Article  PubMed  CAS  Google Scholar 

  47. Pirri C, Bayliss E, Trotter J, Olver IN, Katris P, Drummond P, et al. Nausea still the poor relation in antiemetic therapy? The impact on cancer patients’ quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster. Support Care Cancer. 2013;21:735–48.

    Article  PubMed  Google Scholar 

  48. McLean SL, Blenkinsopp A, Bennett MI. Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. J Pain Palliat Care Pharmacother. 2013;27:132–5.

    Google Scholar 

  49. Ang SK, Shoemaker LK, Davis MP. Nausea and vomiting in advanced cancer. Am J Hosp Palliat Care. 2010;27:219–25.

    Article  PubMed  Google Scholar 

  50. Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manage. 2012;44:604–7.

    Article  PubMed  CAS  Google Scholar 

  51. Thomson K, Henry B. Oncology clinical challenges: caring for patients with preexisting psychiatric illness. Clin J Oncol Nurs. 2012;16:471–80

    Google Scholar 

  52. Baldwin KJ, Zivković SA, Lieberman FS. Neurologic emergencies in patients who have cancer: diagnosis and management. Neurol Clin. 2012;30:101–28.

    Article  PubMed  Google Scholar 

  53. Lorenz RA, Jackson CW, Saitz M. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacotherapy. 2010;30:942–51.

    Article  PubMed  CAS  Google Scholar 

  54. Patkar AA, Pae CU. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27 Suppl 1:29–37.

    Google Scholar 

  55. Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B. Maneeton N Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev. 2013;5, CD007815. doi:10.1002/14651858.CD007815.pub2.

    PubMed  Google Scholar 

  56. Bodén R, Edman G, Reutfors J, Ostenson CG, Osby U. A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. Neuropsychiatr Dis Treat. 2013;9:371–7.

    Article  PubMed  Google Scholar 

  57. Lertxundi U, Hernandez R, Medrano J, Domingo-Echaburu S, García M. Aguirre C Antipsychotics and seizures: higher risk with atypicals? Seizure. 2013;22:141–3.

    Article  PubMed  Google Scholar 

  58. Nooijen PM, Carvalho F, Flanagan RJ. Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum Psychopharmacol. 2011;26:112–9.

    Article  PubMed  CAS  Google Scholar 

  59. Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol. 2006;58(7):871–85.

    Article  PubMed  CAS  Google Scholar 

  60. Clevenger CV, Zheng J, Jablonski EM, Galbaugh TM, Fang F. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J Mammary Gland Biol Neoplasia. 2008;13:147–56.

    Article  PubMed  Google Scholar 

  61. Stiefel F, Berney A, Mazzocato C. Psychopharmacology in supportive care in cancer: a review for the clinician. I. Benzodiazepines. Support Care Cancer. 1999;7:379–85.

    Article  PubMed  CAS  Google Scholar 

  62. Roscoe JA, Morrow GR, Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2011;19:1533–8.

    Article  PubMed  Google Scholar 

  63. Testa A, Giannuzzi R, Sollazzo F, Petrongolo L, Bernardini L. Dain SPsychiatric emergencies (part II): psychiatric disorders coexisting with organic diseases. Eur Rev Med Pharmacol Sci. 2013;17 Suppl 1:65–85.

    PubMed  Google Scholar 

  64. Skrobik Y, Leger C, Cossette M, Michaud V, Turgeon J. Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors. Crit Care Med. 2013;41:999–1008.

    Article  PubMed  CAS  Google Scholar 

  65. Costantini C, Ale-Ali A. Helsten T Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. J Palliat Med. 2011;14:563–6.

    Article  PubMed  Google Scholar 

  66. Joffe H, Partridge A, Giobbie-Hurder A, Li X, Habin K, Goss P, et al. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause. 2010;17:908–16.

    Article  PubMed  Google Scholar 

  67. Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care. Cochrane Database Syst Rev. 2002;4, CD003346.

    PubMed  Google Scholar 

  68. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379:721–8.

    Article  PubMed  CAS  Google Scholar 

  69. • Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013;111:105–11. This review summarizes standard guidelines for the use of anticonvulsants (e.g. pregabalin and gabapentin), antidepressants (e.g. duloxetine and tricyclics), and topical treatments (e.g. capsaicin and lidocaine) in cancer pain, although the authors complain a lack of good-quality clinical trials in cancer-related neuropathic pain.

    Article  PubMed  CAS  Google Scholar 

  70. Pruitt AA. Medical management of patients with brain tumors. Curr Treat Options Neurol. 2011;13:413–26.

    Article  PubMed  Google Scholar 

  71. Maschio M. Brain tumor-related epilepsy. Curr Neuropharmacol. 2012;10:124–33.

    Article  PubMed  CAS  Google Scholar 

  72. Maschio M, Dinapoli L, Mingoia M, Sperati F, et al. Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol. 2011;258:2100–4.

    Article  PubMed  CAS  Google Scholar 

  73. Masand PS, Tesar GE. Use of stimulants in the medically ill. Psychiatr Clin North Am. 1996;19:515–47.

    Article  PubMed  CAS  Google Scholar 

  74. Homsi J, Walsh D, Nelson KA. Psychostimulants in supportive care. Support Care Cancer. 2000;8:385–97.

    Article  PubMed  CAS  Google Scholar 

  75. • Portela MA, Rubiales AS, Centeno C. The use of psychostimulants in cancer patients. Curr Opin Support Palliat Care. 2011;5:164–8. This article reviews the most recent studies that examine the efficacy of psychostimulants for the relief of symptoms such as asthenia and depression in cancer patients.

    Article  PubMed  Google Scholar 

  76. • Minton O, Richardson A, Sharpe M, Hotopf M, Stone PC. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage. 2011;41:761–7. This article summarizes the increasing evidence for the use of psychostimulants, particularly methylphenidate, in the treatment of cancer-related fatigue.

    Article  PubMed  CAS  Google Scholar 

  77. • Breitbart W, Alici Y. Psychostimulants for cancer-related fatigue. J Natl Compr Canc Netw. 2010;8:933–42. This article presents a comprehensive review of the use of psychostimulant agents for fatigue among patients with cancer, including an overview of the clinical trials with psychostimulants and of the clinical guidelines available for treatment of cancer-related fatigue.

  78. Von Ah D, Jansen C, Allen DH, Schiavone RM, Wulff J. Putting evidence into practice: evidence-based interventions for cancer and cancer treatment-related cognitive impairment. Clin J Oncol Nurs. 2011;15:607–15.

    Article  Google Scholar 

  79. Gehring K, Roukema JA, Sitskoorn MM. Review of recent studies on interventions for cognitive deficits in patients with cancer. Expert Rev Anticancer Ther. 2012;12:255–69.

    Article  PubMed  CAS  Google Scholar 

  80. Zafra-Ceres M, de Haro T, Farez-Vidal E, Blancas I, Bandres F, de Dueñas EM, et al. Influence of CYP2D6 Polymorphisms on Serum Levels of Tamoxifen Metabolites in Spanish Women with Breast Cancer. Int J Med Sci. 2013;10:932–7.

    Article  PubMed  CAS  Google Scholar 

  81. Garland SN, Valentine D, Desai K, Li S, Langer C, Evans T, Mao JJ. Complementary and Alternative Medicine (CAM) use and benefit finding among cancer patients. J Altern Complement Med. 2013. doi:10.1089/acm.2012.0964.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Rosangela Caruso declares that she has no conflict of interest.

Luigi Grassi has received royalties from Oxford University Press.

Maria Giulia Nanni declares that she has no conflict of interest.

Michelle Riba declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Institute of Psychiatry, Department of Biomedical and Specialty Surgical Sciences, University of Ferrara, Corso Giovecca 203, 44121, Ferrara, Italy

    Rosangela Caruso, Luigi Grassi & Maria Giulia Nanni

  2. Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA

    Michelle Riba

Authors
  1. Rosangela Caruso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luigi Grassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Giulia Nanni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michelle Riba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luigi Grassi.

Additional information

This article is part of the Topical Collection on Complex Medical-Psychiatric Issues

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caruso, R., Grassi, L., Nanni, M.G. et al. Psychopharmacology in Psycho-oncology. Curr Psychiatry Rep 15, 393 (2013). https://doi.org/10.1007/s11920-013-0393-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11920-013-0393-0

Keywords

Search

Navigation